Target
GIPR
gastric inhibitory polypeptide receptor
Aliases: gastric inhibitory polypeptide receptor · glucose-dependent insulinotropic polypeptide receptor
Mediates GIP-dependent insulin secretion; co-agonism with GLP-1R is thought to enhance weight loss and glycemic control.
Mechanism summary
Mediates GIP-dependent insulin secretion; co-agonism with GLP-1R is thought to enhance weight loss and glycemic control.
Family: G-protein coupled receptor (GPCR), class B
Related indications
Assets targeting this mechanism
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Tirzepatide | Approved | Eli Lilly |
| Retatrutide | Phase 3 | Eli Lilly |
| Maritide | Phase 1/2 | Amgen |
| CT-388 | Phase 1 | Roche |
Competing assets
4 assets are mapped to GIPR. View the asset table above to compare stages and sponsors.